Want to see JP:6568 full AI Analyst Report?

KNC Laboratories Co.,Ltd. (6568) Price & Analysis

0 Followers

6568 Stock Chart & Stats

¥1124.00

¥0.00(0.00%)

At close: Jan 08 4:00 PM EST

¥1124.00

¥0.00(0.00%)

Day’s Range― - ―

52-Week Range¥1,060.00 - ¥1,418.00

Previous CloseN/A

Volume3.20K

Average Volume (3M)2.89K

Market Cap

¥9.87B

Enterprise Value¥10.93K

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)12.8

Beta0.60

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.6%

Share Statistics

EPS (TTM)N/A

Shares Outstanding7,779,900

10 Day Avg. Volume3,150

30 Day Avg. Volume2,890

Financial Highlights & Ratios

PEG Ratio3.29

Price to Book (P/B)0.67

Price to Sales (P/S)1.04

P/FCF Ratio-26.14

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)208.6

Revenue Forecast (FY)¥12.00B

Bulls Say, Bears Say

Bulls Say

Revenue Growth ResumptionAn 11.2% revenue rebound in 2026 signals renewed demand or market recovery after 2025 weakness. Sustained top-line growth provides a foundation for restoring scale economics, supports long-term investment capacity, and is a durable lever for future margin recovery if cost dynamics improve.

Solid Balance Sheet And CapitalizationSteady equity growth and historically low debt-to-equity show strong capitalization. Manageable leverage gives the company financial resilience to weather margin pressure, fund strategic investment or R&D, and access financing on reasonable terms, supporting stability over the medium term.

Operating Cash Flow RecoveryA marked improvement in operating cash flow in 2026 indicates the core business is generating more cash from operations. If sustained, this boosts the firm's ability to fund capex, service debt, and reinstate shareholder returns, improving long-term financial flexibility despite recent FCF setbacks.

Bears Say

Profitability Compression And Margin ErosionMaterial margin compression and lower gross profit despite higher revenue point to adverse pricing, mix shifts, or higher input costs. This weakens earnings power and the company's ability to convert sales into sustainable profits, making recovery dependent on structural cost or pricing fixes.

Consecutive Negative Free Cash FlowTwo years of negative free cash flow reduce financial flexibility and erode the buffer provided by a strong balance sheet. Persistent FCF deficits constrain debt reduction, capex funding, and dividend sustainability, increasing reliance on external financing if the trend continues.

Recent Increase In DebtRising debt amid compressed margins and weak FCF raises refinancing and interest-service risk. Even with moderate leverage historically, higher indebtedness reduces optionality for strategic moves and amplifies downside if profitability and cash generation don't recover over the medium term.

6568 FAQ

What was KNC Laboratories Co.,Ltd.’s price range in the past 12 months?

KNC Laboratories Co.,Ltd. lowest stock price was ¥1060.00 and its highest was ¥1418.00 in the past 12 months.

What is KNC Laboratories Co.,Ltd.’s market cap?

KNC Laboratories Co.,Ltd.’s market cap is ¥9.87B.

When is KNC Laboratories Co.,Ltd.’s upcoming earnings report date?

KNC Laboratories Co.,Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 90 days.

How were KNC Laboratories Co.,Ltd.’s earnings last quarter?

Currently, no data Available

Is KNC Laboratories Co.,Ltd. overvalued?

According to Wall Street analysts KNC Laboratories Co.,Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does KNC Laboratories Co.,Ltd. pay dividends?

KNC Laboratories Co.,Ltd. pays a Semiannually dividend of ¥16 which represents an annual dividend yield of 2.6%. See more information on KNC Laboratories Co.,Ltd. dividends here

What is KNC Laboratories Co.,Ltd.’s EPS estimate?

KNC Laboratories Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does KNC Laboratories Co.,Ltd. have?

KNC Laboratories Co.,Ltd. has 7,779,900 shares outstanding.

What happened to KNC Laboratories Co.,Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of KNC Laboratories Co.,Ltd.?

Currently, no hedge funds are holding shares in JP:6568

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

KNC Laboratories Co.,Ltd.

KNC Laboratories Co., Ltd. engages in research, development, and production solutions for organic chemicals. Its operations are carried out through the following business divisions: Functional Materials Business, Pharmaceutical Business, and Bio Business. The Functional Materials Business division provides display materials, chemicals for semiconductor manufacturing, carbon nanotube dispersions, etc. The Pharmaceutical Business division provides compounds for pharmaceutical research and development. The Bio Business Division provides auxiliary agents for antibody drug manufacturing. The company was founded on January 22, 1985 and is headquartered in Kobe, Japan.